BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 32739472)

  • 1. Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19.
    Mazzitelli M; Davoli C; Scaglione V; Fusco P; La Gamba V; Matera G; Trecarichi EM; Torti C
    Travel Med Infect Dis; 2020; 37():101826. PubMed ID: 32739472
    [No Abstract]   [Full Text] [Related]  

  • 2. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
    Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M
    Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906
    [No Abstract]   [Full Text] [Related]  

  • 3. Problems with the analysis in "Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19".
    Atkinson JG
    Int J Infect Dis; 2020 Oct; 99():37. PubMed ID: 32738492
    [No Abstract]   [Full Text] [Related]  

  • 4. Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".
    Bonny A; Talle MA; Ngantcha M; Tayebjee MH
    Travel Med Infect Dis; 2020; 37():101861. PubMed ID: 32889105
    [No Abstract]   [Full Text] [Related]  

  • 5. Comment on Arshad et al.: Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.
    Varisco TJ; Johnson ML; Thornton D
    Int J Infect Dis; 2020 Oct; 99():373. PubMed ID: 32771630
    [No Abstract]   [Full Text] [Related]  

  • 6. Does Combining Severe and Mild Cases of COVID-19 Produce Low Fatality Rates After Treatment With Hydroxychloroquine and Azithromycin?
    Fleury V
    Am J Epidemiol; 2020 Nov; 189(11):1227-1229. PubMed ID: 32685969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going.
    Parra-Lara LG; Martínez-Arboleda JJ; Rosso F
    J Glob Antimicrob Resist; 2020 Sep; 22():680-684. PubMed ID: 32622008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.
    Bessière F; Roccia H; Delinière A; Charrière R; Chevalier P; Argaud L; Cour M
    JAMA Cardiol; 2020 Sep; 5(9):1067-1069. PubMed ID: 32936266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection.
    Giaime P; Guenoun M; Pedinielli N; Narbonne H; Bergounioux JP; Solas C; Guilhaumou R; Sampol J; Ollier J; Sichez H; Serveaux M; Brunner F; Bataille S
    Nephrol Dial Transplant; 2020 Aug; 35(8):1346-1353. PubMed ID: 32844224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxychloroquine-azithromycin for COVID-19 - Warranted or dangerous?
    Popescu CP; Fischer PR
    Travel Med Infect Dis; 2020; 35():101764. PubMed ID: 32485391
    [No Abstract]   [Full Text] [Related]  

  • 11. Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
    Mégarbane B; Scherrmann JM
    J Clin Pharmacol; 2020 Jul; 60(7):808-814. PubMed ID: 32434282
    [No Abstract]   [Full Text] [Related]  

  • 12. Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend.
    Hor CP; Hussin N; Nalliah S; Ooi WT; Tang XY; Zachariah S; Jugindar Singh GPS; Abdul Rani R; Perumal K; Cheah WK
    J Infect; 2020 Aug; 81(2):e117-e119. PubMed ID: 32474031
    [No Abstract]   [Full Text] [Related]  

  • 13. Safe use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center.
    Pothen L; Yildiz H; De Greef J; Penaloza A; Beauloye C; Belkhir L; Yombi JC
    Travel Med Infect Dis; 2020; 36():101788. PubMed ID: 32540396
    [No Abstract]   [Full Text] [Related]  

  • 14. An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19.
    Intson K; Kumar S; Botta A; Neckles R; Leung C; Jawaid A
    Swiss Med Wkly; 2020 Apr; 150():w20262. PubMed ID: 32347963
    [No Abstract]   [Full Text] [Related]  

  • 15. Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19.
    Rosenberg ES; Holtgrave DR; Udo T
    Int J Infect Dis; 2020 Oct; 99():38-39. PubMed ID: 32738483
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.
    Arshad S; Kilgore P; Chaudhry ZS; Jacobsen G; Wang DD; Huitsing K; Brar I; Alangaden GJ; Ramesh MS; McKinnon JE; O'Neill W; Zervos M;
    Int J Infect Dis; 2020 Aug; 97():396-403. PubMed ID: 32623082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.
    Ahn BY; Kang CK; Seo JD; Choe PG; Song SH; Park WB; Park SW; Kim NJ; Oh MD
    J Korean Med Sci; 2020 Jun; 35(24):e231. PubMed ID: 32567262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?
    d'Arminio Monforte A; Tavelli A; Bai F; Marchetti G; Cozzi-Lepri A
    Int J Infect Dis; 2020 Oct; 99():75-76. PubMed ID: 32738491
    [No Abstract]   [Full Text] [Related]  

  • 19. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.
    Okour M; Al-Kofahi M; Austin D
    J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):187-188. PubMed ID: 32405664
    [No Abstract]   [Full Text] [Related]  

  • 20. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.
    Furtado RHM; Berwanger O; Fonseca HA; Corrêa TD; Ferraz LR; Lapa MG; Zampieri FG; Veiga VC; Azevedo LCP; Rosa RG; Lopes RD; Avezum A; Manoel ALO; Piza FMT; Martins PA; Lisboa TC; Pereira AJ; Olivato GB; Dantas VCS; Milan EP; Gebara OCE; Amazonas RB; Oliveira MB; Soares RVP; Moia DDF; Piano LPA; Castilho K; Momesso RGRAP; Schettino GPP; Rizzo LV; Neto AS; Machado FR; Cavalcanti AB;
    Lancet; 2020 Oct; 396(10256):959-967. PubMed ID: 32896292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.